Alumis

Alumis P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Alumis (ALMS) as of Oct 21, 2026 is -8.55. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -12.32 — a change of -30.62% (higher).

P/FCF

-8.55

YoY

-30.62%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alumis is 2025 -8.55 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Alumis was 2024 -12.32 . It decreases by -30.62% higher compared to the previous year.

The Alumis P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2022
-28.74 USD
Jan 1, 2023
-23.53 USD
Jan 1, 2024
-12.32 USD
Jan 1, 2025
-8.55 USD
The Alumis P/FCF history
YEARP/FCFYoY
-8.55-30.62%
-12.32-47.64%
-23.53-18.10%
-28.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Alumis Stock analysis

What does Alumis do? Alumis Inc develops TYK2 inhibitors ESK-001 and A-005 for immune-mediated and neuroinflammatory diseases. ESK-001 targets plaque psoriasis, systemic lupus erythematosus, and Uveitis as a second-generation allosteric inhibitor. A-005 is designed as a CNS-penetrant molecule for neurodegenerative conditions. The company builds a pipeline using data analytics to identify targets for immune-mediated indications. Its products are developed for clinical-stage biopharmaceutical use, targeting specific disease mechanisms with optimized tolerability. The company focuses on developing therapies as monotherapy or combination treatments for immune-mediated diseases. ESK-001 maximizes target inhibition while optimizing tolerability for psoriasis and lupus. A-005 delivers TYK2 inhibition within the central nervous system for neuroinflammatory diseases. The pipeline includes early-stage discovery assets identified through the company's data analytics platform, targeting immune-mediated conditions without specifying additional therapeutic applications. Alumis Inc's revenue model is based on the development and potential future commercialization of its TYK2 inhibitor pipeline. The company's products target specific disease areas including plaque psoriasis, systemic lupus erythematosus, Uveitis, and neurodegenerative conditions. The clinical-stage focus indicates that revenue will likely come from partnerships, licensing agreements, or eventual product sales once approved. The company's data analytics platform supports target identification for immune-mediated indications, which may lead to additional pipeline assets. Alumis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alumis stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alumis is -8.55 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Alumis changed from -12.32 to -8.55, representing a -30.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Alumis since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Alumis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Alumis

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Alumis